VRPX vs. NAVB, SYRS, SMFL, SCPS, STAB, EVLO, CMRA, GNCAQ, GNCA, and ARDS
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Syros Pharmaceuticals (SYRS), Smart for Life (SMFL), Scopus BioPharma (SCPS), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.
Virpax Pharmaceuticals vs. Its Competitors
Virpax Pharmaceuticals (NASDAQ:VRPX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Virpax Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 beat Navidea Biopharmaceuticals' score of -0.80 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.
Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals.
Summary
Navidea Biopharmaceuticals beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRPX) was last updated on 9/4/2025 by MarketBeat.com Staff
